FDA approved drug Exondys 51 made by Sarepta Therapeutics to treat Duchenne muscular dystrophy. Improving the Patient Financial Experience Throughout the Patient Journey While many healthcare ...
Despite recent U.S. Food and Drug Administration approval, health insurer Anthem said it won’t cover the expensive biotech drug eteplirsen for Duchenne muscular dystrophy, saying the prescription is ...
Indianapolis-based payer Anthem said it will not cover Sarepta Therapeutics’ recently approved Duchenne muscular dystrophy drug, Reuters reports. Sarepta gained U.S. Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback